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Abstract
MicroRNAs are a class of small non-coding RNAs that 
are found in plants, animals, and some viruses. They 
modulate the gene function at the post-transcriptional 
level and act as a fine tuner of various processes, such 
as development, proliferation, cell signaling, and apopto-
sis. They are associated with different types and stages 
of cancer. Recent studies have shown the involvement 
of microRNAs in liver diseases caused by various factors, 
such as Hepatitis C, Hepatitis B, metabolic disorders, and 
by drug abuse. This review highlights the role of microR-
NAs in liver diseases and their potential use as therapeu-
tic molecules. 
© 2009 The WJG Press and Baishideng. All rights reserved.
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INTRODUCTION
The recent discovery of  several types of  non-coding RNAs 
revealed that the transcriptomes of  higher eukaryotes are 
much more complex than originally anticipated. The non-
coding RNAs, including microRNAs (miRNA), piwi in-
teracting RNAs, small nucleolar RNAs, small interfering 
RNAs, long non-coding RNAs and antisense RNAs, have 
newly-discovered roles in the biology of  health and dis-
eases. These RNAs serve as modulators of  genes involved 
in various biological pathways, such as development, cell 
differentiation, cell proliferation, cell death, chromosome 
modifications, virus pathogenesis, and oncogenesis[1-3]. 
Among these RNAs, miRNAs are small RNA molecules 
of  approximate 21 nucleotides that are present in most eu-
karyotes[4]. Since the discovery of  the first miRNA, lin-4, in 
1993[5], more than 500 miRNAs have been reported in the 
mammalian genome[6]. 
It is postulated that about 1%-5% of  genes in ani-
mals encode miRNAs, while 10%-30% of  protein-
coding genes are predicted miRNA targets[7,8], and have 
a specific miRNA signature in normal or cancer cells[9,10]. 
Although our understanding of  the specific roles of  
miRNAs in cellular functions is only beginning, several 
studies have shown that miRNAs play a pivotal role in 
the most critical biological events, including develop-
ment, proliferation, differentiation, cell fate determina-
tion, apoptosis, signal transduction, organ development, 
hematopoietic lineage differentiation, host-viral interac-
tions, and carcinogenesis[4,11-13]. 
Overview of miRNAs 
Despite the emerging critical role of  miRNAs, the 
mechanism of  their action is yet to be fully understood. 
The widely-known mode of  gene regulation by miRNAs 
occurs at the post-transcriptional level by either specific 
inhibition of  translation or induction of  mRNA cleavage[14]. 
The essential role of  miRNAs in cellular physiology was 
elegantly shown in mice lacking the Dicer enzyme that is 
required for the processing of  the precursor miRNAs into 
the mature form[15]. 
Until now, the major focus of  miRNA research was 
on their role in the cytoplasm, however recent reports 
indicate a diverse role of  miRNAs, such as regulation of  
target genes by acting at 5’ UTR[16], regulation of  DNA 
methylation[17,18] and import of  the mature miRNA into 
the nucleus, suggesting other functional modes[19]. It is 
becoming clear that miRNAs not only regulate gene 
expression at the post-transcriptional level, but they are 
also capable of  modifying chromatin (Figure 1). 
In this review, we discuss the role of  the newly 
emerging class of  RNA, miRNAs, in different types of  
liver diseases.
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MiRNAs IN LIVER DISEASES
Improvements in the characterization and functional 
analysis techniques for miRNAs has not only uncovered 
their role in various cellular processes, but also revealed 
abnormal patterns of  miRNA expression in various 
diseases, such as cancer[20], viral infection[21], inflam-
mation[22], diabetes[23], cardiovascular[24], and Alzheimer[25]. 
In this review, we focus on the involvement of  miRNAs 
in liver diseases caused by various factors, such as viral 
hepatitis, fatty liver due to alcohol abuse or metabolic 
syndrome, drug-induced liver disease, and by auto-
immune processes (summarized in Table 1). 
MiRNAs in host-viral response and viral hepatitis
Viruses are equipped with complex machinery to exploit 
the host biosynthetic pathways and to defend against 
host cellular responses[26]. Recent studies have revealed 
the involvement of  miRNA-mediated RNA-silencing 
pathways during viral-host cell interactions[27]. However, 
little is known about the role of  cellular miRNAs against 
viral infection in eukaryotic organisms. Interestingly, 
viruses not only exploit the cellular miRNAs, but also 
encode their own miRNAs, adding another layer of  
complexity[28,29]. Therefore, it is important to study the 
abundance and distribution of  miRNAs within the host 
cell during viral replication and latency, which will help 
us to understand the molecular regulation by the host 
cellular system as well as the simultaneous attempts by 
viruses to overcome the host defense. 
Role of  miRNAs in immune response: The interac-
tion of  parenchymal and immune cells plays a unique 
role in the liver in response to liver insults by viruses, 
bacteria, toxins, or antigens. There is compelling evi-
dence that characterizes miRNAs as key regulators of  in-
nate and adaptive immune responses[22,30] and, therefore, 
they might play a role in inflammatory, autoimmune, or 
viral diseases of  the liver. The importance of  miRNAs 
in the liver immune system is highlighted by the fact that 
mice lacking Dicer 1 function in the liver were unable to 
produce mature miRNA and showed progressive hepa-
tocyte damage, apoptosis, and portal inflammation[31]. 
The innate immune response is the first line of  de-
fense against noxious agents and is mediated by adaptors, 
such as the toll like receptors (TLRs), which recognize 
specific molecular patterns. Signals triggered by TLRs 
are involved in most liver diseases (from viral to inflam-
matory conditions) as well as in liver regeneration[32]. 
Several miRNAs (such as miR-155 or miR-146a/b) have 
been implicated in the regulation of  TLR-induced signal-
ing and might associated with liver pathophysiology. In 
particular, miR-155 was upregulated in monocytes and 
macrophages both upon TLR2, TLR3, TLR4, and TLR9 
stimulation and after exposure to cytokines such as tumor 
necrosis factor (TNF)-α and interferons (IFN)[33-35]. The 
exact function of  this miRNA in macrophages is not 
completely clear, but it might exert a positive regulation 
on TNF-α release, through targeting genes involved in 
nuclear factor-κB (NF-κB) signaling or enhancing TNF-α 
translation[34]. miR-146 is also upregulated in response to 
TLR2, TLR4, and TLR5 stimulation in monocytes[33]. This 
miRNA seems to decrease the release of  inflammatory 
mediators, such as interleukin (IL)-1β or IL-8[36], possibly 
by downregulating IL-1 receptor-associated kinase 1 and 
TNF receptor-associated factor 6, and act as a negative 
regulator of  TLR signaling[33]. Most of  the studies describ-
ing the importance of  these miRNAs in the innate im-
mune response have been performed in macrophages or 
monocytes in vitro, and therefore the elucidation of  spe-
cific miRNA functions in vivo in Kupffer cells, the resident 
liver macrophage, still awaits confirmation. 
Neutrophil leukocyte infiltration in the liver is also a 
part of  the innate immune response, which is common to 
liver injury, hepatic stress, or systemic inflammation sig-
nals[37]. Regulators of  granulocyte function and activation, 
such as miR-223, might also be able to play a role in liver 
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Table 1  Expression of miRNAs in liver diseases
Liver Upregulated Downregulated Ref.
HCV miR-215, miR-16, miR-199, 
miR-155, miR-146
miR-122, miR-320, 
miR-191
[53]
HBV miR-181a, miR-200b and 
miR-146a
miR-15a [56]
Drug 
overdose
miR-711 (liver), miR-29b(liver), [62]
Plasma: miR-122 miR-15a, 
miR-21, miR-101b,  miR-
148a and miR-192
miR-710 (plasma)
NAFLD miR-122, miR-34a, miR-31, 
miR-103, miR-107, miR-194, 
miR-335-5p, miR-221 and 
miR-200a
miR-29c, miR-451, 
miR-21
[69,70] 
ALD miR-212, miR-320, miR-486, 
miR-705, and miR-1224
miR-27b, miR-214, 
miR-199a-3p, 
miR-182, miR-183, 
miR-200a, and 
miR-322
 [71,72]
PBC miR-328 and miR-299 miR-122a and miR-
26a
[73]
Liver 
fibrosis
miR-27a, miR-27b,miR-30, miR-9,miR-721 and 
miR-301
[80]
HCC miR-18, miR-21, miR-221, 
miR-222, miR-224, miR-373 
and miR-301
miR-122, miR-125, 
miR-130a, miR-150, 
miR-199, miR-200 and 
let-7 family members
[81,90-95]
HCV: Hepatitis C virus; HBV: Hepatitis B virus; NAFLD: Non-alcoholic 
fatty liver disease; ALD: Alcoholic liver disease; PBC: Primary biliary 
cirrhosis; HCC: Hepatocellular carcinoma.
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Figure 1  Various modes of gene regulation by miRNAs.
MicroRNAs
disease. Several reports have shown that the transcription 
factor C/EBPα binds to the miR-223 promoter and en-
hances its expression[38-40]. Given the importance of  anti-
gen presentation in the liver, the involvement of  miRNAs 
in this function could be also of  interest. In line with this, 
Hashimi et al[41] have recently shown that inhibition of  
both miR-21 and miR-34a in monocyte-derived dendritic 
cells led to a decrease in endocytic capacity and altered 
differentiation. 
Apart from their role in the innate immune responses, 
miRNAs are associated with many aspects of  both normal 
and abnormal immune adaptive responses, making them 
likely actors in autoimmune liver diseases or, particularly, 
viral hepatitis[22,30]. Virtually every T and B cell type seems 
to be associated with a different miRNA expression pro-
file, and therefore an interesting avenue of  research is to 
identify the miRNAs signature associated with specific liv-
er diseases. Regarding specific miRNA functions, miR-181 
has been described as a key quantitative regulator of  T cell 
response to antigens[42]. MiR-150 plays a crucial role in B 
cell differentiation because its over-expression results in a 
selective defect in B cell development that blocks the tran-
sition from pro-B cell to pre-B cell[43]. Of  note, miR-155 
is implicated in both T and B cell function and differentia-
tion promoting T helper 1 vs type 2 differentiation[44,45] and 
is essential in the production of  antigen-specific antibod-
ies[46]. These data highlight the importance of  this miRNA 
as a central actor in immune regulation.
Hepatitis C virus (HCV) infection: HCV is an envel-
oped RNA virus of  the Flavivirus family, and is capable 
of  causing both acute and chronic hepatitis in humans 
by infecting liver cells. It is a major cause of  chronic 
liver disease, with about 170 million people infected 
worldwide[47]. Up to 70% of  patients will have persistent 
infection after inoculation, making it a fatal disease. The 
disease varies widely, from asymptomatic chronic infec-
tion to cirrhosis and hepatocellular carcinoma (HCC)[47]. 
Since the discovery of  HCV, the treatment of  hepatitis 
C has considerably improved by the use of  pegylated 
interferons with ribavirin; however, more than 50% of  
people still do not respond to current medication and 
thus there is need for better drug therapy. 
Recent studies have shown the involvement of  
miRNAs in the regulation of  HCV infection. MiR-122 
is first identified liver-specific cellular miRNA, which 
has been shown to enhance the replication of  HCV by 
targeting the viral 5’ non-coding region[48]. It appears 
that HCV replication is associated with an increase in 
expression of  cholesterol biosynthesis genes that are 
regulated by miR-122 and hence is considered as a 
potential target for antiviral intervention[49].
To date, there are some controversies around the 
role of  miR-122 in HCV infection. Recently, Henke 
et al[50] showed that miR-122 stimulates HCV translation 
by enhancing the association of  ribosomes with the 
viral RNA. The findings describing the role of  miR-122 
in HCV replication are of  special interest, not only 
because of  its novel mode of  action, but because they 
also provide the first evidence of  miRNAs linked to 
infectious disease. The development of  therapeutic 
products to inhibit the miR-122 is believed to be an 
attractive approach to treat HCV patients.
By contrast, Sarasin-Filipowicz et al[51] found that liver 
biopsies from chronic hepatitis C patients undergoing 
IFN therapy revealed no correlation between miR-122 
expression and viral load. Moreover, they found markedly 
decreased miR-122 levels in people who did not have 
any virological response during later IFN therapy. These 
reports indicate that the role of  miR-122 in HCV viral 
replication is still controversial and awaits future research. 
While some host miRNAs are beneficial for the 
virus, others inhibit viral replication. Studies by Pedersen 
et al[52] demonstrated that IFN-β stimulation, an antiviral 
cytokine, induces numerous cellular miRNAs, specifically 
eight miRNAs (miR-1, miR-30, miR-128, miR-196, 
miR-296, miR-351, miR-431 and miR-448) that have 
sequence-predicted targets within the HCV genomic RNA. 
Overexpression of  these miRNAs in infected liver cells 
considerably attenuated viral replication. From this report it 
seems that host miRNAs have evolved to target viral genes 
and inhibit their replication, and thus might represent part 
of  the host antiviral immune response. Very recently, Peng 
et al[53] carried out a computational study of  hepatitis C 
virus associated miRNAs-mRNA regulatory modules in 
human livers. They found differential profiles of  cellular 
miRNAs that target the genes involved in chemokine 
(16 genes such as CXCL12 etc.), B cell receptor, PTEN 
(13 genes), IL-6 ERK/ MAPK (18 genes; Ras, Erk3 and 
STAT3 etc.) and JAK/STAT signaling pathways, suggesting 
a critical role of  miRNAs in the replication, propagation, 
and latency of  virus in the host cell. Specifically, they found 
that miR-122, miR-320, and miR-191 were downregulated, 
whereas miR-215, miR-16, miR-26, miR-130, miR-199 and 
miR-155 were upregulated. These findings suggest that 
miRNAs have the potential to become novel drug targets 
in virally induced infectious or malignant diseases.
Hepatitis B virus (HBV) infection: HBV infection is 
a global problem and it can cause acute or chronic hepa-
titis B, liver cirrhosis, and, in some instances HCC[54]. 
The available therapy is only partially effective against 
the virus and development of  better therapy remains an 
important issue. Little is known about the involvement 
of  miRs during HBV infection. Considering the fact that 
cellular miRNAs play an important role in viral patho-
genesis, it is likely that they have a role in HBV infection.
A differential miRNAs expression pattern was found 
in the livers of  HBV and HCV infected individuals 
with hepatocellular cancer[55]. A total of  nineteen 
miRNAs were clearly differentiated between HBV and 
HCV groups, out of  which thirteen miRNAs were 
downregulated in the HCV group, whereas six showed 
a decreased expression in the HBV group. Some of  
the differentially regulated miRNAs between the HCV 
and HBV groups were miR-190, miR-134, miR-151, 
miR-193, miR-211, and miR-20. Interestingly, in the 
same study, it was shown that pathway analysis of  
targeted genes using infection-associated miRNAs could 
differentiate the genes into two groups. For instance, 
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in HBV-infected livers, pathways related to cell death, 
DNA damage, recombination, and signal transduction 
were activated, and those related to immune response, 
antigen presentation, cell cycle, proteasome, and lipid 
metabolism were activated in HCV-infected livers[55]. 
In a second study, the profiling of  cellular miRNAs 
of  a stable HBV expressing cell line HepG2.2.15 and its 
parent cell line HepG2, showed that eighteen miRNAs 
were differentially expressed between the two cell 
lines[56]. Of  them, eleven were upregulated and seven 
were downregulated. For instance, miR-181a, miR-200b, 
and miR-146a were found to be upregulated and miR-
15a was downregulated. It remains to be evaluated if  
differentially regulated miRNAs could be exploited as 
potential biomarkers to differentiate between HCV and 
HBV in the initial stages of  pathogenesis.
MiRNAs in drug-induced liver injury
Drug-induced liver injury is a serious clinical health 
problem and is the leading cause of  drugs being removed 
from the market[57]. Acetaminophen overdose is the most 
common cause of  fulminant liver failure. Many studies 
have been carried out to identify reliable and sensitive 
early blood markers for liver injury using high throughput 
technologies[58]. However, these efforts have so far failed 
to yield markers that are superior compared to the existing 
aminotransferase-based markers, and the need for better 
and stable biomarkers persists. Increasing attention is 
being paid to circulating miRNAs as potential biomarkers 
because of  their stability over enzymes or proteins[59-61]. 
However, not much is known about the roles of  miRNAs 
in drug-induced liver injury. A study by Wang et al[62] 
showed differential miRNAs profiling in a mouse model 
of  acetaminophen overdose. Significant differences were 
found in the levels of  miRNAs in both liver tissues and 
plasma between control and acetaminophen overdosed 
animals. Using miRPortal (www.miRportal.net), pathways 
involving antigen processing and presentation, apoptosis, 
B cell receptor signaling pathways, cytokine-cytokine 
receptor interaction, and cell cycles were found to be 
potential targets of  miRNAs that showed decreased levels 
in the liver after acetaminophen exposure. In contrast, 
pathways involved in various signaling transduction and 
cell-cell interactions, such as gap-junctions, focal adhesion, 
and MAPK signaling pathways were potentially affected 
by miRNAs with increased levels in the liver[62]. 
Interestingly, it was observed that most miRNAs that 
were found to decrease in the liver exhibited increased levels 
in the plasma in overdosed mice. For instance, miR-122 
and miR-192 showed higher levels in plasma, but they were 
decreased in tissue, whereas miR-710 and miR-711 were 
elevated in liver tissues; however, they displayed lower levels 
in plasma after acetaminophen overdose. Moreover, liver 
specific miRNAs, such as miR-122 and miR-192, showed 
dose and time-dependent changes in the plasma that 
paralleled serum aminotransferase levels and liver injury 
on histopathology. These findings suggest the potential 
of  using specific circulating miRNAs as sensitive and 
informative biomarkers for drug-induced liver injury.
MiRNAs in non-alcoholic fatty liver disease (NAFLD)
NAFLD is the most common form of  chronic liver 
disease worldwide and a major public health concern in 
the modern society[63]. It is characterized by excess fat ac-
cumulation in liver, which ranges from simple steatosis 
to steatohepatitis, and cirrhosis in the absence of  heavy 
alcohol consumption[64]. The major risk factors for the de-
velopment of  NAFLD include metabolic syndrome, such 
as obesity, type 2 diabetes mellitus, and dyslipidemia[65]. 
Although progress has been made in understanding the 
factors causing NAFLD, more needs to be done to dissect 
the underlying regulatory networks. Compelling evidences 
indicate the role of  miRNAs in energy metabolism and 
liver functions[66,67]. For instance, miR-143 has been shown 
to play a role in adipose differentiation[68]. 
MiR-122, which was found to be upregulated in 
NAFLD, is known to regulate genes involved in fatty 
acid biosynthesis[69], and administration of  this miRNA 
antagonist into mice resulted in reduced levels of  plasma 
cholesterol, increased hepatic fatty acid oxidation, and 
decreased synthesis of  hepatic fatty acid and cholesterol.
Li et al[70] reported that eight miRNAs (miR-34a, 
miR-31, miR-103, miR-107, miR-194, miR-335-5p, 
miR-221 and miR-200a) were upregulated and three miR-
NAs (miR-29c, miR-451, miR-21) were downregulated in 
the livers of  ob/ob mice. These findings suggested a con-
nection between miRNAs and metabolic disorders, and the 
role of  miRNA in NAFLD deserves further investigation.
Role of miRNAs in alcoholic liver disease (ALD)
ALD, alcoholic hepatitis, and cirrhosis represent a major 
segment of  liver diseases worldwide. A recent report 
by Dolganiuc et al[71] analyzed the miRNA expression 
profile in a murine model of  ALD. Liver samples from 
mice fed an ethanol-containing diet (Lieber-DeCarli) 
showed features of  alcoholic steatohepatitis and had an 
increased expression of  miR-320, miR-486, miR-705, 
and miR-1224. On the other hand, decreased expres-
sion was found for several miRNAs, including miR-27b, 
miR-214, miR-199a-3p, miR-182, miR-183, miR-200a, 
and miR-322. Furthermore, livers from mice with alco-
holic and with non-alcoholic fatty liver shared common 
alterations in their miRNA profiles (such as upregulation 
of  miR-705 and miR-1224). However, the functions and 
physiological roles of  these miRNAs in ALD are yet 
to be determined. Tang et al[72] have suggested a novel 
mechanism for ethanol-induced intestinal permeability. 
They found that ethanol intake resulted in the induction 
of  miR-212, which in turn downregulated the Zonula 
occludens (ZOP) protein. The decrease in ZOP protein 
levels led to intestinal barrier disruption and thus in-
creased intestinal permeability. The interest of  this find-
ing lies in the association of  intestinal permeability with 
the development of  ALD, therefore linking miR-212 
with the pathogenesis of  this disease.
Primary biliary cirrhosis (PBC)
Recent studies indicate that the role of  miRNAs is yet to 
be explored in liver diseases associated with autoimmune 
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aggression. In PBC, altered hepatic miRNA expression 
was found[73]. miRNA profiling of  explanted livers from 
subjects with PBC revealed differential expression of  
thirty-five independent miRNAs compared to controls. 
Downregulation of  miR-122a and miR-26a, and increased 
expression of  miR-328 and miR-299, were confirmed 
by PCR in the PBC livers. The role of  miRNAs in 
autoimmune hepatitis is yet to be studied.
Liver fibrosis
Chronic hepatitis contributes to liver fibrosis, which 
has been linked to fibrosis due to fibrin deposition by 
hepatic stellate cells (HSC)[74]. The relationship between 
miRNAs and fibrosis has been shown in the context 
of  specific diseases, such as diabetic kidney sclerosis[75] 
or myocardial fibrosis[76], and some of  the mechanisms 
described could be involved in common pathways of  
fibrosis in other diseases. A recent report by Kato et al[77] 
has described that transforming growth factor (TGF)-β 
activates Akt kinase by enhancing the expression of  
both miR-216a and miR-217. These miRNAs, in turn, 
target PTEN, an inhibitor of  Akt activation that has 
also been described to play a role in hepatic stellate cell 
activation[78]. Hepatic stellate cell activation has been 
identified as the major driver of  liver fibrosis. Activation 
of  HSC is associated with upregulation of  various 
signaling pathways. In cirrhotic rat livers, HSC activation 
was associated with mitochondrial damage indicated 
by increased Bcl-2 and downregulated caspase-9 levels. 
The miRNA profile of  the same rat HSC indicated 
upregulation of  thirteen and downregulation of  twenty-
two, signaling pathways by miRNAs[79]. In another in 
vitro study, overexpression of  miR-27a and miR-27b 
resulted in reversal of  the activated phenotype of  stellate 
cells to a more quiescent phenotype with increased fat 
accumulation and decreased proliferation[80]. The effects 
of  miR-27a and miR-27b were mediated by regulation 
of  the retinoid X receptor in the hepatic stellate cells. 
Although there are only a few studies in the literature 
on miRNA genes and HCV-induced liver fibrosis, given 
the critical role of  miRNA, its possible that they play 
a critical role in HCV infection, in the progression of  
fibrosis, and in the prediction of  treatment response. Jiang 
et al[81] showed increased miRNA expression in cirrhotic 
and hepatitis-positive liver samples and suggested that 
important changes in miRNA expression occur during the 
development of  chronic viral hepatitis and cirrhosis.
 
HCC
HCC is the third-leading cause of  death from cancer 
and the fifth most common malignancy worldwide[82]. 
Liver cancer is a complex disease with exceptional 
heterogeneity in cause and outcome, involving epigenetic 
and chromosomal instability[83] and abnormalities in 
the expression of  both coding and non-coding genes, 
including miRNAs[84,85]. The major etiologies of  HCC 
include chronic liver disease due to chronic hepatitis B 
or hepatitis C virus infection, alcoholic steatohepatitis, 
metabolic disorders such as nonalcoholic steatohepatitis 
or insulin resistance, hereditary hemochromatosis, and 
immune-related diseases such as PBC and autoimmune 
hepatitis[86].
There are several studies in the literature showing 
specific miRNA signatures in HCC formation[87-89] and 
progression that could be exploited as potential cancer 
biomarkers. Briefly, miR-18, miR-21, miR-221, miR-222, 
miR-224, miR-373, and miR-301 were reported to be 
upregulated[81,90,91] whereas miR-122, miR-125, miR-130a, 
miR-150, miR-199, miR-200, and let-7 family mem-
bers[92-95] were found to be downregulated in HCC by most 
studies. These miRNAs target the genes involved in cell 
cycle and cell death regulation, including cyclin-dependent 
inhibitors p27/CDKN1B and p57/CDKN1C, or the PI3K 
antagonist phosphatase and tensin homolog (PTEN). 
Budhu et al[96] defined twenty miRNAs, as a HCC metas-
tasis signature, and showed that the twenty-miRNA-based 
signature was capable of  predicting survival and recur-
rence of  HCC in patients with multinodular or solitary tu-
mors, including those with early-stage disease. miR-219-1, 
miR-207, and miR-338 were the most highly upregulated, 
whereas miR-34a, miR-30c-1, and miR-148a were highly 
downregulated in metastasis cases. Target Scan analysis 
revealed that SPTBN2, GTF2H1, PSCD3, VAMP3, and 
SLC20A2 are the target genes which were affected by 
multiple miRNAs related to metastasis and might be the 
part of  signaling pathways that significantly contribute to 
this phenotype. Moreover, this miRNA signature was an 
independent and significant predictor of  patient prognosis 
when compared to other available clinical parameters[96]. 
This study suggested that these twenty miRNAs can as-
sist in HCC prognosis and might have clinical relevance. 
Further functional studies of  these miRNAs could help 
to elucidate the mechanism leading to HCC metastasis. 
Deregulation of  these twenty miRNAs in metastatic 
HCC implies that altered expression of  their target genes 
might contribute to the development or recurrence of  
metastasis, and miR-122 is one example of  this metastasis 
signature[97].
THE POTENTIAL OF MiRNAs IN 
DIAGNOSTICS, DISEASE PROGNOSIS, 
AND THERAPY
Increasing evidence indicates that miRNAs play an 
important role in a wide range of  liver diseases, ranging 
from cancers and viral hepatitis, to metabolic diseases. 
The unique expression profile of  miRNAs in different 
types and at different stages of  cancer, and in other 
diseases, suggest that these small molecules can be 
exploited as novel biomarkers for disease diagnostics and 
might present a new strategy for miRNA gene therapy.
Recently, Kota et al[98] showed that administration of  
miR-26a, (which is under-expressed in HCC cells and 
downregulates cyclins D2 and E2) using adeno-associated 
virus (AAV) resulted in the inhibition of  cancer cell 
proliferation, induction of  tumor-specific apoptosis, 
and dramatic protection from disease progression 
without toxicity in a mouse model of  HCC, suggesting 
the potential therapeutic use of  miRNAs. This study 
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showed that anti-miRNA compounds could be delivered 
in vivo safely and with efficacy; thus opening the way for 
translation of  these basic research findings to clinical 
applications. It is also important to consider other factors, 
because some miRNA genes such as miR-1 undergo 
methylation-mediated regulation in HCC cell lines[99], 
suggesting a strong link between the DNA methylome 
and the miRNAome. In particular, there are some reports 
showing that the expression profiles of  miRNA differ 
between malignant hepatocytes, malignant cholangiocytes, 
and benign liver cancer[90], suggesting that miRNA 
profiling could be used as molecular diagnostic markers in 
liver disease.
CONCLUSION 
It is increasingly evident that miRNAs play a novel and 
important role in regulation of  gene expression. In 
recent years, research focusing on small molecules such 
as miRNAs has intensified to understand their role in 
health and disease. The excitement of  exploring their 
regulatory potential will remain for years to come, given 
the observation that miRNAs could be ideal therapeutic 
targets for many diseases. We are at the beginning of  
understanding of  the diverse roles of  miRNAs in fine-
tuning biological pathways, and in future years we 
will have a better picture of  this complex regulatory 
mechanism. Presently, there is need for miRNAs-based 
diagnostics and gene therapy; however, these techniques 
are in their infancy. 
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